The targeted drugs especially EGFR tyrosine kinase inhibitors (EGFR-TKIs) bring significant benefits for the NSCLC patients harboured the mutant gene and improves the 5-year survival of patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.